mRNA-1273 COVID-19 vaccine-induced Steven–Johnson syndrome

Lo, Hung-Kai; Lin, Yan; Chen, Hung-Ming; Hsiao, Po-Jen

doi:10.1093/qjmed/hcac282

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zou and Daveluy [103] collected 12 cases with TEN/SJS after COVID-19 vaccinations [83,102,[104][105][106][107][108][109][110][111][112][113] along with 22 cases with TEN/SJS after COVID-19 infection, which had been reported until August 2022. Seven additional case reports (7 patients) of vaccine-related SJS/TEN were found at the time of manuscript writing in Oct 2023 [114][115][116][117][118][119][120] . Vaccines used in 19 patients were Moderna-1273 (n = 6), BNT162b2 (n = 4), ChAdOx1 nCoV-19 (n = 4) and BBIBB-CorV (n = 5).…”

Section: Iii) Erythema Multiforme Typementioning

confidence: 99%

The pathophysiology and clinical phenotypes of COVID-19 mRNA vaccine-related cutaneous adverse reactions: A narrative review

Ishikawa

2024

Trends Immunother.

View full text Add to dashboard Cite

Cutaneous adverse reactions (CARs) after COVD-19 messenger ribonucleic acid (mRNA) vaccines have been reported worldwide, but the pathophysiology of CARs remains to be elucidated. To understand the pathophysiology, it is essential to know how the innate and adaptive immunity are activated after vaccination. At present, majority of CARs are presumed to be evoked by innate immunity response. Reviewing the previous articles, I propose the clinical classification of CARs; local injection site reaction, generalized eruption, localized eruption and others. Since COVID-19 mutates continuously to overcome the existing vaccines, our steady efforts are indispensable to clarify the pathophysiology of CARs and contribute to the development of novel vaccines with least adverse events and high efficacy.

show abstract